Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2015

01-07-2015

Impact of red blood cells count and high density lipoproteins with the prevalence and extent of coronary artery disease

Authors: Alon Schaffer, Monica Verdoia, Ettore Cassetti, Lucia Barbieri, Pasquale Perrone-Filardi, Paolo Marino, Giuseppe De Luca

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2015

Login to get access

Abstract

We have hypothesized that high red blood cells (RBC) count can potentially play an atheroprotective role in patients with coronary atherosclerosis. We, therefore, have investigated the relationship between high density lipoproteins cholesterol (HDL-C) and RBC levels in patients undergoing coronary angiography. Coronary artery disease (CAD) is a major cause of mortality. Impaired lipid profile represents a major risk factor for atherosclerosis. High density lipoprotein (HDL) is a key factor in atherosclerosis disease development. RBC can mimic HDL’s reverse cholesterol transportation with a potential atheroprotective role. Coronary angiography has been evaluated in 3,534 patients. Fasting samples were collected for haematology and lipids levels assessment. Coronary disease was defined for at least 1 vessel stenosis >50 %. Patients were divided according to HDL-C and RBC tertiles. Lower HDL-C was significantly associated to the prevalence of CAD (84.8 vs 78.5 vs 67.3 %, p ≤ 0.001; adjusted OR [95 % CI] = 1.55 [1.3–1.8], p < 0.001) and severe CAD (30 % vs 30 % vs 24.4 %, p = 0.002; adjusted OR [95 % CI] = 1.08 [1.01–1.16], p = 0.02), this relationship was maintained even dividing our population according to RBC tertiles (p < 0.001).In conclusion, HDL-C levels are directly related to RBC count and inversely to the prevalence and extent of coronary disease. Higher RBC levels can reduce the risk of CAD in patients with lower HDL-C levels, suggesting an important atheroprotective role.
Literature
1.
go back to reference Karalis DG (2009) Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease. Mayo Clin Proc 84:345–352CrossRefPubMedCentralPubMed Karalis DG (2009) Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease. Mayo Clin Proc 84:345–352CrossRefPubMedCentralPubMed
2.
go back to reference Libby P (2005) The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 46:1225–1228CrossRefPubMed Libby P (2005) The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 46:1225–1228CrossRefPubMed
3.
go back to reference Miller GJ, Miller NE (1975) Plasma-highdensity- lipoprotein concentration and development of ischaemic heart-disease. Lancet 1:16–19CrossRefPubMed Miller GJ, Miller NE (1975) Plasma-highdensity- lipoprotein concentration and development of ischaemic heart-disease. Lancet 1:16–19CrossRefPubMed
4.
go back to reference Castelli WP, Garrison RJ, Wilson PW (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256:2835–2838CrossRefPubMed Castelli WP, Garrison RJ, Wilson PW (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256:2835–2838CrossRefPubMed
5.
go back to reference 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34:2949–3003 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34:2949–3003
6.
go back to reference Glomset JA (1968) The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 9:155–167PubMed Glomset JA (1968) The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 9:155–167PubMed
7.
go back to reference Hill SA, McQueen MJ (1997) Reverse cholesterol transport–a review of the process and its clinical implications. Clin Biochem 30:517–525CrossRefPubMed Hill SA, McQueen MJ (1997) Reverse cholesterol transport–a review of the process and its clinical implications. Clin Biochem 30:517–525CrossRefPubMed
8.
go back to reference Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135CrossRefPubMedCentralPubMed Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135CrossRefPubMedCentralPubMed
9.
go back to reference Tziakas DN, Kaski JC, Chalikias GK, Romero C, Fredericks S, Tentes IK, Kortsaris AX, Hatseras DI, Holt DW (2007) Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J Am Coll Cardiol 49:2081–2089CrossRefPubMed Tziakas DN, Kaski JC, Chalikias GK, Romero C, Fredericks S, Tentes IK, Kortsaris AX, Hatseras DI, Holt DW (2007) Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J Am Coll Cardiol 49:2081–2089CrossRefPubMed
10.
go back to reference De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Franchi E, Coppo L, Iorio S, Venegoni L, Rondano E, Dell’Era G, Rizzo C, Pergolini P, Monaco F, Bellomo G, Marino P (2009) Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis 206:292–297CrossRefPubMed De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Franchi E, Coppo L, Iorio S, Venegoni L, Rondano E, Dell’Era G, Rizzo C, Pergolini P, Monaco F, Bellomo G, Marino P (2009) Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis 206:292–297CrossRefPubMed
11.
go back to reference De Luca G, Secco GG, Santagostino M, Venegoni L, Iorio S, Cassetti E, Verdoia M, Coppo L, Di Mario C, Bellomo G, Marino P, Novara Atherosclerosis Study Group (NAS) (2012) Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 22:426–433CrossRefPubMed De Luca G, Secco GG, Santagostino M, Venegoni L, Iorio S, Cassetti E, Verdoia M, Coppo L, Di Mario C, Bellomo G, Marino P, Novara Atherosclerosis Study Group (NAS) (2012) Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 22:426–433CrossRefPubMed
12.
go back to reference De Luca G, van ‘t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata H (2005) Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty Eur Heart J 26:662–666 De Luca G, van ‘t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata H (2005) Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty Eur Heart J 26:662–666
13.
go back to reference De Luca G, Verdoia M, Suryapranata H (2012) Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. Atherosclerosis 222:426–433CrossRefPubMed De Luca G, Verdoia M, Suryapranata H (2012) Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. Atherosclerosis 222:426–433CrossRefPubMed
14.
go back to reference De Luca G, Dirksen M, Spaulding C (2012) Drug-eluting versus bare metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 172:611–621CrossRefPubMed De Luca G, Dirksen M, Spaulding C (2012) Drug-eluting versus bare metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 172:611–621CrossRefPubMed
15.
go back to reference De Luca G, Ernst N, van’t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata H (2006) Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J 151:1256–1259CrossRefPubMed De Luca G, Ernst N, van’t Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata H (2006) Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J 151:1256–1259CrossRefPubMed
16.
go back to reference De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M, Huber K, Van’t Hof AW (2009) Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 207:181–185CrossRefPubMed De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M, Huber K, Van’t Hof AW (2009) Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 207:181–185CrossRefPubMed
17.
go back to reference De Luca G, Verdoia M, Cassetti E, Schaffer A, Cavallino C, Bolzani V, Marino P, Novara Atherosclerosis Study Group (NAS) (2011) High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. J Thromb Thrombolysis 31:458–463CrossRefPubMed De Luca G, Verdoia M, Cassetti E, Schaffer A, Cavallino C, Bolzani V, Marino P, Novara Atherosclerosis Study Group (NAS) (2011) High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. J Thromb Thrombolysis 31:458–463CrossRefPubMed
18.
go back to reference De Luca G, Venegoni L, Iorio S, Secco GG, Cassetti E, Verdoia M, Schaffer A, Coppo L, Bellomo G, Marino P, Novara Atherosclerosis Study Group (2010) Platelet distribution width and the extent of coronary artery disease: results from a large prospective study. Platelets 21:508–514CrossRefPubMed De Luca G, Venegoni L, Iorio S, Secco GG, Cassetti E, Verdoia M, Schaffer A, Coppo L, Bellomo G, Marino P, Novara Atherosclerosis Study Group (2010) Platelet distribution width and the extent of coronary artery disease: results from a large prospective study. Platelets 21:508–514CrossRefPubMed
19.
go back to reference De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Coppo L, Schaffer A, Fundaliotis A, Iorio S, Venegoni L, Bellomo G, Marino P (2010) Platelet-large cell ratio and the extent of coronary artery disease: results from a large prospective study. J Thromb Thrombolysis 30:426–433CrossRefPubMed De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Coppo L, Schaffer A, Fundaliotis A, Iorio S, Venegoni L, Bellomo G, Marino P (2010) Platelet-large cell ratio and the extent of coronary artery disease: results from a large prospective study. J Thromb Thrombolysis 30:426–433CrossRefPubMed
20.
go back to reference Gordon DJ, Rifkind BM (1989) High-density lipoproteindthe clinical implications of recent studies. N Engl J Med 321:1311–1316CrossRefPubMed Gordon DJ, Rifkind BM (1989) High-density lipoproteindthe clinical implications of recent studies. N Engl J Med 321:1311–1316CrossRefPubMed
21.
go back to reference Assman G, Cullen P, Schulte H (1998) The Münster Heart Study (PROCAM), results of follow-up at 8 years. Eur Heart J 19:A2–A11 Assman G, Cullen P, Schulte H (1998) The Münster Heart Study (PROCAM), results of follow-up at 8 years. Eur Heart J 19:A2–A11
22.
go back to reference Cziraky MJ, Watson KE, Talbert RL (2008) Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 14:S3–28PubMed Cziraky MJ, Watson KE, Talbert RL (2008) Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 14:S3–28PubMed
23.
go back to reference High patient compliance with nicacin/laropiprant in large clinical trial interim safety and tolerability results from HPS-2 THRIVE study released at 2012 ESC congress: drug trends in cardiology. (2012) Cardiovasc J Afr 23: 471 High patient compliance with nicacin/laropiprant in large clinical trial interim safety and tolerability results from HPS-2 THRIVE study released at 2012 ESC congress: drug trends in cardiology. (2012) Cardiovasc J Afr 23: 471
24.
go back to reference Acharjee S, Boden WE, Hartigan PM, Teo KK, Maron DJ, Sedlis SP, Kostuk W, Spertus JA, Dada M, Chaitman BR, Mancini GB, Weintraub WS (2013) Low levels of high density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post hoc analysis from the COURAGE Trial. J Am Coll Cardiol 62:1826–1833CrossRefPubMed Acharjee S, Boden WE, Hartigan PM, Teo KK, Maron DJ, Sedlis SP, Kostuk W, Spertus JA, Dada M, Chaitman BR, Mancini GB, Weintraub WS (2013) Low levels of high density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post hoc analysis from the COURAGE Trial. J Am Coll Cardiol 62:1826–1833CrossRefPubMed
26.
go back to reference Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr (1982) Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 2:16–26CrossRefPubMed Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr (1982) Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 2:16–26CrossRefPubMed
27.
go back to reference Buchwald H, O’Dea TJ, Menchaca HJ, Michalek VN, Rohde TD (2000) Effect of plasma cholesterol on red blood cell oxygen transport. Clin Exp Pharmacol Physiol 27:951–955CrossRefPubMed Buchwald H, O’Dea TJ, Menchaca HJ, Michalek VN, Rohde TD (2000) Effect of plasma cholesterol on red blood cell oxygen transport. Clin Exp Pharmacol Physiol 27:951–955CrossRefPubMed
28.
go back to reference Nara M, Sumino H, Nara M, Machida T, Amagai H, Nakajima K, Murakami M (2009) Impaired blood rheology and elevated remnant-like lipoprotein particle cholesterol in hypercholesterolaemic subjects. J Int Med Res 37:308–317CrossRefPubMed Nara M, Sumino H, Nara M, Machida T, Amagai H, Nakajima K, Murakami M (2009) Impaired blood rheology and elevated remnant-like lipoprotein particle cholesterol in hypercholesterolaemic subjects. J Int Med Res 37:308–317CrossRefPubMed
29.
go back to reference Schaffer A, Verdoia M, Barbieri L, Aprami TM, Suryapranata H, Marino P, De Luca G; on behalf of the Novara Atherosclerosis Study Group (NAS) (2013) High-density lipoproteins and coronary artery disease: a Single-Center Cohort Study. Angiology 18. [Epub ahead of print] Schaffer A, Verdoia M, Barbieri L, Aprami TM, Suryapranata H, Marino P, De Luca G; on behalf of the Novara Atherosclerosis Study Group (NAS) (2013) High-density lipoproteins and coronary artery disease: a Single-Center Cohort Study. Angiology 18. [Epub ahead of print]
30.
go back to reference Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R (2003) Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349:2316–2325CrossRefPubMed Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R (2003) Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349:2316–2325CrossRefPubMed
31.
go back to reference Asterkamp G, Virmani R (2002) The erythrocyte: a new player in atheromatous core formation. Heart 88:115–116CrossRef Asterkamp G, Virmani R (2002) The erythrocyte: a new player in atheromatous core formation. Heart 88:115–116CrossRef
32.
go back to reference Steinvil A, Rogowski O, Banai S, Leshem-Rubinow E, Halkin A, Keren G, Finkelstein A, Mashav N, Zuzut M, Berliner S, Arbel Y (2015) Anemia and inflammation have an additive value in risk stratification of patients undergoing coronary interventions. J Cardiovasc Med (Hagerstown) 16:106–111 Steinvil A, Rogowski O, Banai S, Leshem-Rubinow E, Halkin A, Keren G, Finkelstein A, Mashav N, Zuzut M, Berliner S, Arbel Y (2015) Anemia and inflammation have an additive value in risk stratification of patients undergoing coronary interventions. J Cardiovasc Med (Hagerstown) 16:106–111
33.
go back to reference Kitai Y, Ozasa N, Morimoto T, Bao B, Furukawa Y, Nakagawa Y, Kadota K, Yanagita M, Shizuta S, Kimura T; CREDO-Kyoto registry investigators (2013) Prognostic implications of anemia with or without chronic kidney disease in patients undergoing elective percutaneous coronary intervention. Int J Cardiol 168:5221–5228 Kitai Y, Ozasa N, Morimoto T, Bao B, Furukawa Y, Nakagawa Y, Kadota K, Yanagita M, Shizuta S, Kimura T; CREDO-Kyoto registry investigators (2013) Prognostic implications of anemia with or without chronic kidney disease in patients undergoing elective percutaneous coronary intervention. Int J Cardiol 168:5221–5228
34.
go back to reference Ganelina IE, Rodionova VI, Katiukhin LN, Tepliakov DV (2011) Data of coronary angiography and rheological properties of erythrocytes in non ST-elevation acute coronary syndrome. Kardiologiia 51:4–9PubMed Ganelina IE, Rodionova VI, Katiukhin LN, Tepliakov DV (2011) Data of coronary angiography and rheological properties of erythrocytes in non ST-elevation acute coronary syndrome. Kardiologiia 51:4–9PubMed
35.
go back to reference Madjid M, Fatemi O (2013) Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update. Tex Heart Inst J 40:17–29PubMedCentralPubMed Madjid M, Fatemi O (2013) Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update. Tex Heart Inst J 40:17–29PubMedCentralPubMed
36.
go back to reference Hung KT, Berisha SZ, Ritchey BM, Santore J, Smith JD (2012) Red blood cells play a role in reverse cholesterol transport. Arterioscler Thromb Vasc Biol 32:1460–1465CrossRefPubMedCentralPubMed Hung KT, Berisha SZ, Ritchey BM, Santore J, Smith JD (2012) Red blood cells play a role in reverse cholesterol transport. Arterioscler Thromb Vasc Biol 32:1460–1465CrossRefPubMedCentralPubMed
37.
go back to reference Nikolić M, Stanić D, Antonijević N, Niketić V (2004) Cholesterol bound to hemoglobinin normal human erythrocytes: a new form of cholesterol in circulation? Clin Biochem 37:22–26CrossRefPubMed Nikolić M, Stanić D, Antonijević N, Niketić V (2004) Cholesterol bound to hemoglobinin normal human erythrocytes: a new form of cholesterol in circulation? Clin Biochem 37:22–26CrossRefPubMed
38.
go back to reference Levy Y, Leibowitz R, Aviram M, Brook JG, Cogan U (1992) Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolaemia. Br J Clin Pharmacol 34:427–430PubMedCentralPubMed Levy Y, Leibowitz R, Aviram M, Brook JG, Cogan U (1992) Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolaemia. Br J Clin Pharmacol 34:427–430PubMedCentralPubMed
39.
go back to reference Martínez M, Vayá A, Martí R, Gil L, Lluch I, Carmena R, Aznar J (1996) Erythrocyte membrane cholesterol/phospholipid changes and hemorheological modifications in familial hypercholesterolemia treated with lovastatin. Thromb Res 83:375–388CrossRefPubMed Martínez M, Vayá A, Martí R, Gil L, Lluch I, Carmena R, Aznar J (1996) Erythrocyte membrane cholesterol/phospholipid changes and hemorheological modifications in familial hypercholesterolemia treated with lovastatin. Thromb Res 83:375–388CrossRefPubMed
40.
go back to reference Hassani SE, Mintz GS, Fong HS, Kim SW, Xue Z, Pichard AD (2006) Negative remodeling and calcified plaque in octogenarians with acute myocardial infarction: an intravascular ultrasound analysis. J Am Coll Cardiol 47:2413–2419CrossRefPubMed Hassani SE, Mintz GS, Fong HS, Kim SW, Xue Z, Pichard AD (2006) Negative remodeling and calcified plaque in octogenarians with acute myocardial infarction: an intravascular ultrasound analysis. J Am Coll Cardiol 47:2413–2419CrossRefPubMed
Metadata
Title
Impact of red blood cells count and high density lipoproteins with the prevalence and extent of coronary artery disease
Authors
Alon Schaffer
Monica Verdoia
Ettore Cassetti
Lucia Barbieri
Pasquale Perrone-Filardi
Paolo Marino
Giuseppe De Luca
Publication date
01-07-2015
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2015
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-015-1174-x

Other articles of this Issue 1/2015

Journal of Thrombosis and Thrombolysis 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.